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gous transplantation as the alternative to haploidentical
transplantation at centers without a haploidentical pro-
gram. The transplant conditioning regimens and graft-ver-
sus-host disease prophylaxis regimens in their report are
heterogeneous and it is challenging to distinguish between
transplant center expertise and the transplantation strategy.
Furthermore, the mid-sized and smaller transplant pro-
grams are unlikely to have the necessary infrastructure,
volume or funds to develop transplantation programs. On
the other hand, conducting well-designed multicenter clin-
ical trials that will allow mid- and small-sized centers to
adopt strategies developed at the larger centers will permit
the adoption of emerging strategies and likely improve sur-
vival after hematopoietic cell transplantation.3,4 One could
argue that most transplant centers are competent at per-
forming adult unrelated donor transplants in recent years.
Recently, Khera and colleagues compared transplantation
outcomes of participants enrolled on Blood and Marrow
Transplant Clinical Trials Network (BMTCTN) 0201 to
those of participants who were potentially eligible by
virtue of known characteristics.5 BMTCTN 0201 was con-
ducted in North America and randomized primarily adult
patients with acute or chronic leukemia or myelodysplastic
syndromes to receive either bone marrow or peripheral
blood with myeloablative transplant conditioning regi-
mens and calcinuerin inhibitor-containing graft-versus-host
disease prophylaxis.6 Based on known characteristics, 494
of 1384 potentially eligible patients were enrolled on
BMTCTN 0201 based on the database of the Center for
International Blood and Marrow Transplant Research. In
multivariate analysis, after adjusting for risk factors associ-
ated with mortality, no significant difference in mortality
risk for non-trial participants compared to trial participants
(hazard ratio 1.09, P=0.22) was demonstrated.5
Selecting donors for hematopoietic cell transplantation in
the absence of an HLA-matched sibling is challenging.7
Observational transplant registries are an invaluable
resource for studying transplantation outcomes. However,
investigators have an obligation to ensure that the groups of
interest are comparable not just regarding patient and dis-
ease characteristics but also transplant strategies including
conditioning regimen, graft-versus-host disease prophylaxis
and graft source. This would allow for objective interpreta-
tion of the findings as well as data for planning clinical trials.
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“The impact of demographic aging within the European Unionis likely to become of major significance… The share of thoseaged 80 years or above is predicted to almost triple between
2011 and 2060”. This statement convinced the board of the
European Hematology Association (EHA) to define “aging“
as the theme of the year in 2013 and to launch a new
Scientific Working Group (SWG) on “Aging and
Hematology” in 2014.1
Due to this demographic shift, 60% of patients with
malignant hemopathies are today older than 65 years and
this proportion will continue to increase in the future.
Cancer, like chronic diseases, increases exponentially after
the age of 50 years. This is the result of a combination of
both intrinsic (immune senescence, genetic and epigenetic
alterations) and extrinsic events (longer exposure to carcino-
gens, chronic antigenic stimulation).  
Although malignant hemopathies (myelodysplasia,
leukemia, lymphoma, myeloma, etc.)2,3 are a major cause of
concern in this age group, other hematologic issues (ane-
mia,4 cardiovascular problems requiring anticoagulation,
etc.) also require specific attention and clear recommenda-
tions.
Aging and hematologic cancers
Aging is a complex process influenced by genetic vari-
ables as well as environmental factors.5 It leads to the vul-
nerability of older patients: a decreased function of various
organs already weakened by chronic diseases and the
increased susceptibility to infections and carcinogenic
genetic damages.  The hematopoietic stem cell (HSC) is
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not spared by this aging process where DNA damage,
telomerase shortening, oxidative stress and poor homing
efficiency have been reported.6,7 Such genetic and epige-
netic damage to the HSC result in malignant hemopathies
in a population with a median age over 65 years. In addi-
tion, older patients with acute myeloid leukemia often
present with poor prognosis cytogenetic abnormalities (-7,
7q-, -5, 5q-) that negatively impact clinical outcome with
poor overall survival.8,9 The reason for the increased inci-
dence of these poor prognosis leukemias in the elderly is
not fully understood.
Thus, research in this field remains critical to further understand
the vulnerability of these older patients on the physical, cellular and
molecular levels.
Biomarkers predictive of survival and treatment-related
toxicity
In addition to age and diagnosis, shortened overall sur-
vival in cancer patients is correlated with impaired function-
al and nutritional status,10 comorbidities,11 polypharmacy,
and mental health.12 A recent review of various malignant
hemopathies also revealed that functional dependence,
comorbidities, abnormal cognitive function, depression and
limited social support were associated with treatment-relat-
ed complications leading to loss of autonomy after
chemotherapy.13 However, some clinically fit patients,
referred to receive full-dose chemotherapy, presented unex-
pected treatment-related, and sometimes life-threatening,
side-effects. On the contrary, some patients deemed clini-
cally vulnerable tolerated full-dose treatment.
Thus, more accurate biomarkers are urgently needed to better
identify the patients who may or may not benefit from standard
treatment.
The increased mortality in elderly patients is not only
related to their fragility and poor tolerance to chemothera-
py. Indeed, oncologists tend to reduce the doses of treat-
ment in older patients in order to avoid potentially fatal
side-effects such as febrile neutropenia, thereby decreasing
the chances of therapeutic success. Furthermore, patients
and their families, fearing a loss of autonomy, will also push
physicians to cut back on the doses of treatment.  These
patients in poor physical or psychological conditions are too
often excluded from prospective studies, even though they
represent the population we most often have to face in our
daily practice.14
Clinical trials must now enroll patients with co-morbidi-
ties and impaired functions in order to define guidelines for
this specific population.15
A multidisciplinary evaluation
To avoid toxicities and loss of independence after and
during treatment, hemato-oncologists collaborate with geri-
atricians to identify “clues” of vulnerability in older patients
through the study of various functional parameters:  physi-
cal, physiological, cognitive, social and psychological.
These comprehensive geriatric assessments (CGA) have
undoubtedly improved the supportive care of vulnerable
older patients through a better management of their (some-
times unsuspected) problems.16,17 However, some of the
deficiencies detected during these evaluations are related to
the disease itself and are thus likely to improve with treat-
ment. Therefore, each patient should benefit from a colle-
gial decision to adapt the curative and/or supportive
approach that takes into account the reversibility of such
co-morbidities.
If the multidisciplinary approach brings together the concerns of
geriatricians and hemato-oncologists, the additional involvement
of the patient himself/herself and the general practitioner involved
would result in better patient care, including further support at
home if needed.
Besides CGA, the screening tool G8 is among the most
frequently studied screening tool applied in geriatric oncol-
ogy so far. It correlates with functional decline after three
months of follow up, chemotherapy-related toxicity, and
survival.18 The G8 scoring includes age and 7 questions
derived from the "Mini Nutritional Assessment". In trials
that compared G8 and CGA, the sensitivity varied between
65% and 92%, while specificity varied between 30% and
75%, respectively. However, in hemato-oncology, the pre-
dictive value of G8 is penalized by the negative impact of
the tumor on the nutritional status of the patient, thus lead-
ing to an overestimation of the patients’ frailty,19 and conse-
quently, to unnecessary dose reduction!  Our prospective
study, aimed at determining the respective values of G8 and
CGA in terms of 1-year survival in a selected population of
“clinically fit” patients, failed to show a beneficial role of G8
(sensitivity 79.2%, specificity 55.6%). However, it empha-
sized the role of CGA that showed the significant predictive
value of mild cognitive impairment on 1-year survival,
which was completely underestimated by the G8 screening
tool.20
A geriatric assessment can detect unknown health prob-
lems in 50% of older (70+ years) patients, yet a large Belgian
study conducted in a very heterogeneous group of cancer
patients indicated that the addition of the comprehensive
geriatric assessment (CGA) to the clinical evaluation of the
oncologist influenced the treatment decision in only 25% of
cases, and mainly concerned the systemic treatment.21
These observations indicate that awareness of oncologists
and hemato-oncologists is still in its infancy, but the reality
on the ground should change our habits.
A multi-step approach 
The traditional approach for younger cancer patients
does not take into account the heterogeneity of the older
cancer population. The challenge for hemato-oncologists is
the appraisal of each older patient through a multi-step pro-
cedure:
a) evaluate the patient’s physiological age and life
expectancy by taking into account the co-morbidities;
b)  accurately assess the tumor’s prognosis and the risks
for the patient of dying from it; 
c) estimate the patient’s tolerance of treatment according
to his physiological, neuro-psychological, nutritional and
socio-economic parameters; 
d) weigh the patient’s risk/benefit ratio taking into
account PROs (patient reported outcomes) and quality of
life;
c) finally, properly inform the patient of the therapeutic
possibilities and decide with him or her whether quality or
length of life should be the primary objective.
Today, with a life expectancy of 80 years or older, collab-
oration between hemato-oncologists and geriatricians is
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essential to optimize older patients’ management. It allows
us to identify patients who may benefit and tolerate the rec-
ommended doses of treatment and those who, on the con-
trary, might suffer side-effects resulting in a decreased qual-
ity of life and that loss of autonomy so feared by the elderly
population!
This multidisciplinary approach should also be applied to older
patients with non-malignant diseases, i.e. patients who require
treatments that may impair their organ function or deteriorate their
quality of life if not properly adapted to their physiological age (i.e.
new anticoagulants for cardiovascular problems).
Conclusions
Although substantial clinical advances have been
achieved in the management of older patients with malig-
nant and non-malignant hemopathies, this new EHA SWG
on “Aging and Hematology” aims to provide attendees with
the latest insights in the field, to highlight the gaps in our
knowledge, to gather our strengths, to better define the
objectives of clinical trials, and thus, to stimulate ideas for
future fundamental, translational and clinical research. 
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